Arrowhead Pharmaceuticals, Inc. - Common Stock - Nakit Akışı (NASDAQ:ARWR)

Financials

İşletme faaliyetlerinden elde edilen nakit -95.39 M171.22 M-136.13 M-153.89 M-462.85 M179.55 M -36.31 M Yatırım faaliyetlerinden elde edilen nakit -240.78 M-141.68 M-5.42 M-96.16 M-420.07 M-129.29 M -704.01 M Finansman faaliyetlerinden elde edilen nakit 257.95 M11.3 M65.19 M253.05 M870.52 M74.01 M 741.96 M Serbest nakit akışı -95.39 M171.22 M-136.13 M-153.89 M-462.85 M156.89 M -50.87 M

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead's products in development act through RNA interference mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease.

ARWR

Financials

Arrowhead Pharmaceuticals, Inc. - Common Stock

Haberler

Arrowhead böbrek ve karaciğer yetmezliğinde plozasiran verisi sundu

These Are The Upcoming Catalysts For Crispr Therapeutics Stock (NASDAQ:CRSP)

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Arrowhead Pharmaceuticals hissesi 80,5 dolarla zirve yaptı

Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2026 Earnings Call Transcript

Sarepta's Q1 Earnings & Sales Beat Estimates, '26 Outlook Maintained

Why This Biotech ETF — The IBD Stock Of The Day — Just Reentered Its Buy Zone

JPMorgan, Arrowhead Pharma hissesini ağırlıklı al ile başlattı

Arrowhead CFO 934.285 dolarlık hisse sattı

Arrowhead Pharmaceuticals CMO 750.000 dolarlık hisse sattı

Stocks Fall as Iran Refuses to Attend Peace Talks

Stocks Erase Early Gains as Crude Prices Jump on Iran Concerns